1) Much awaited P21 data reported through 10th cohort. 2) 10th cohort completion and launch of super potent 11th (likely MTD). 3) Add'l Brilacidin data compiled and submitted to FDA. 4) Phase 3 B-ABSSSI meeting and trial approval. 5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting. 6) Nasdaq Capital Market Uplisting approval and transition. 7) Stellar and reputable BOD announcements 8) B-OM trial UP and RUNNING!!! 9) Ulcerative Proctitis pre-IND FDA meeting 10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible). 11) Coverage initiation (strong buy) by one or more institutional research analysts. 12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.